TY - JOUR
T1 - Lipid-lowering Therapy in Patients With High Cardiovascular Risk
T2 - Dose or Combination?
AU - Roever, Leonardo
AU - Biondi-Zoccai, Giuseppe
AU - Rao, Sunil V.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.
AB - Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.
KW - cardiovascular risk
KW - dyslipidemia
KW - lipids
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=85012885139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012885139&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2017.01.029
DO - 10.1016/j.clinthera.2017.01.029
M3 - Article
C2 - 28190598
AN - SCOPUS:85012885139
VL - 39
SP - 659
EP - 660
JO - Clinical Therapeutics
JF - Clinical Therapeutics
SN - 0149-2918
IS - 3
ER -